Here’s the latest CBD news:
The results of a study recently published in the British Journal of Pharmacology show that KLS-13019, a structural analog of CBD, may be significantly more effective than CBD for “mechanical sensitivity,” pain, and desire to self-administer morphine.
KLS-13019 is very similar to the CBD molecule in its structure (hence, structural analog), but it has been modified by bio-pharmaceutical company Kannalife, who originally derived the compound, to ideally outperform CBD in absorption capability, overall potency, and other dimensions.
In the study, researchers tested both KLS-13019 and CBD on mice with chemo-drug-induced mechanical sensitivity, also assessing the other two issues mentioned: pain-relieving capability and effect(s) on morphine self-administration tendencies.
Here are the key takeaways from the results, as reported by the study authors:
It’s unclear at this point whether cannabinoid-based analogs like KLS-13019 would be regulated and/or legalized by the FDA, should the agency deliver on promises to regulate CBD.
Already rife with fake celebrity endorsement scams, the CBD and cannabis industries have lately had to contend with a sharp uptick in free-trial scams, an issue prevalent enough to earn the attention of the Better Business Bureau (BBB).
In this article on BBB.org, the bureau explains that their scam tracker has registered a rising number of reports from customers “who thought they signed up for a free trial offer but ended up getting billed for hundreds of dollars.”
Generally, this is how these scams work:
The safest course of action is, of course, to avoid free CBD trials altogether, but if you really want to check out a product, the BBB recommends researching the company thoroughly, closely reading the terms of the offer, and quickly reporting fraudulent charges on your credit card to your bank.
A joint venture between leading CBD brand Medterra and Canada-based cannabis investment firm Acreage Holdings will involve a new product rollout from Five CBD, a Medterra subsidiary.
The CBD products to be developed under this deal will be labeled with Acreage’s brand name: The Botanist.
Medterra will handle fulfillment using their e-commerce platform, while Five will list, advertise, and sell these products as per usual.
As explained by Medterra co-founder J.P. Larsen in the company’s announcement of the joint venture, “Incorporating Acreage’s The Botanist brand under Five Farms will allow us to innovate for their target demographic and rapidly expand the brand’s national footprint – it’s an evolution for both industries and the future of CBD and cannabis companies.”
In what will be their first foray into the American market, The Valens Company has closed a cash deal for all outstanding Green Roads shares, agreeing to pay $40 million USD upfront, with provisions allowing for up to $20 million USD more if Green Roads can hit certain milestones thereafter.
According to The Valens Company CEO Tyler Robson, “After analyzing over a hundred companies across the US CBD market, we clearly recognized the value in the Green Roads platform with its best-selling brand.”